Model Number 3CX*FX15RW40C |
Device Problem
Use of Device Problem (1670)
|
Patient Problem
Hemorrhage/Bleeding (1888)
|
Event Date 01/11/2023 |
Event Type
Injury
|
Manufacturer Narrative
|
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11.(b)(4).
|
|
Event Description
|
The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, the patient's blood was not sufficiently oxygenated.Per facility, after an unsatisfactory blood gas analysis, the hlm including the set was replaced.The patient's height is 168 centimeters.Patient's birth year: 1948, bfarm reference: (b)(4).There was approximately 5-10 minutes of delay, the product was changed out, the surgery was completed successfully, there was approximately 250 ml of blood loss.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on february 1, 2023.Upon further investigation of the reported event, the following information is new and/or changed: g6 (indication that this is a follow-up report).H2 (follow-up due to additional information).H3 (device evaluation anticipated by manufacturer - a second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11.).All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Event Description
|
Additional information from the clinical specialist states that, a partial pump record and one blood gas result was provided by the customer.From this record, it can be seen that after initiating bypass at 17:38, and with a suboptimum pump blood flow of only 3.5 l/min (at target cardiac index of 2.5m2 the blood flow should have been 4.75l/min), a blood gas result was taken at 17:41.This revealed the following: ph 7.27, pco2 50mmhg, po2 112mmhg.With gas sweep of 6 liters and fio2 setting of 100%.It is interesting to note from the one blood gas result, that the arterial blood saturation was 98 %, which is within an acceptable range.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: g6 (indication that this is a follow-up report).H2 (follow-up due to additional information and device evaluation).H6 (identification of evaluation codes 10, 3331, 213, 67).Type of investigation #1: 10 - testing of actual/suspected device.Type of investigation #2: 3331 - analysis of production records.Investigation finding: 213 - no device problem found.Investigation conclusions: 67 - no problem detected.The actual sample was visually inspected and no anomaly such as breakage was found.After rinsing and drying the sample, the amount of oxygen transfer and carbon dioxide gas removal were measured according to the product inspection procedure and met the factory's specifications, and no anomaly was found.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Search Alerts/Recalls
|
|